Chris Heminway, Exec-Chair at Time To ACT, explains why now is the right time for the Group to IPO. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Following on from SOG’s excellent post, I’d imagine all those interested will of already approached Tim with figures depending on the CTA and potential treatment paths, he’s just gotta sift through them all and find the one with the most ‘0’s at the end of it :+)
You are welcome HBD
It may take a little while to get to a pound plus.
I fell we will have in a short while:-
News of CTA ie success and start date. Importantly too is if we have 1 or maybe 2 1801 compounds. Our patent allows us to use any of the compounds in any ratio from the 3 groups 00, 01 and 02. Both the iv and oral route to be taken I would think with iv being utilised first..
Maybe Sierra milestone payment, but in honesty I think they delay until got shot of Momelotinib. As Thoth stated a while ago work will need to be done progressing CHK1 or it will be returned. Reduced milestone payment and still not found anything. They have had over a year now to explore options. They just don't have the funds at the moment. 50 million I believe was raised by the issue of more shares. No guarantee as far as I know that it is for CHK1 and not Momolotinib. Milestone payments to Gilead of approx $185million will become due. Bum deal I feel that one for Sierra, Upfront payment I believe of circa 3 million dollars. Gilead must be rubbing their hands together. Plus they have Remsdisivir, that is not worth a wa.k either.
Should our SDC1801 prove successful in Agile platform then further funding can be obtained up to a maximum of 10 million.
I feel we have interested parties that will want to see the outcome of CTA and potential use of 1801.
The price by then will of course have gone up considerably if they want to buy, lock stock and barrel.
SDC was aimed for treatment of Covid 19. It is just that fortunately Covid 19 will prove an ideal testing target for 1801.
With a tail wind behind us we should be in a position to be able to treat people towards the end of the year.
Not overly keen on biological chemistry, much more interest in Nuclear Physics.
I have posted enough on here for while so we leave you all in peace for a it
Regards
SOG - thanks for the thorough reply.
If it all comes together we're heading north of a quid.
Good morning HBD.
The application made in 2019 if memory serves me correct was for Tyk2 1801. This was rejected I believe on the grounds that the compound was already covered under the patent of FLT3. The patent for Tyk2 went through I believe earlier this year.
Effectively. that means patent protection of another 7 years ie runs from circa 2020 as opposed to 2013. Will add considerably to value of compound on proven success. Recent patent grant for Tyk 2 in March for Europe. Almost identical wording to US patent application. All hurdles that need to crossed how now been crossed with regards to patents.
original problem I believe in rejecting earlier application being argued the compound being too similar to FLT3 + Auorora and hence covered by that patent.
Patents with regards to Sareum will provide protection for their compounds and their intended uses.
Regards.
*patent, not parent
HBD - I know one parent had been rejected/turned down and was being argued, but unsure of which one and why, but it sounded like just a formality. One of the experts will be along to answer your question properly like Fadec, RMM, Krone or Citizen et all
'Scuse my ignorance on this but I'm no patent lawyer -
There is a US patent application dated 25/3/21 - https://uspto.report/patent/app/20210087154
The abstract states, "The invention provides a method of inhibiting a TYK2 kinase, which method comprises bringing into contact with the TYK2 kinase an effective TYK2 kinase-inhibiting amount of a compound having the formula (0): or a salt or stereoisomer thereof. The invention also provides a novel subset of compounds within formula (0) as well as pharmaceutical compositions containing them and their use in medicine. ##STR00001##".
There is another application appearing to cover the same thing (as far as I can tell anyway!) filed 13/3/19 - https://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s1=10882829.PN.&OS=PN/10882829&RS=PN/10882829
If they are not for different things, is it simply the newer one is just a 'new & improved' version of the earlier one?
You'd think I had better things to do on a Saturday evening....maybe I'll go and dust behind the skirting board.